Patient-Derived Organoids & Assays for Cancer Research 

This webinar was presented on June 08, 2021

Webinar Summary

With the increasing use of 3D cell structures for modeling tumors, organs, and tissue for translation research, there is a requirement for cancer models, assays and workflows to study patient-derived samples. In this webinar the speakers will present efforts of a successful collaboration of using our automated assay system (the Pu·MA System) with patient-derived organoids for developing an efficient workflow which was incorporated into a translational project which addressed therapeutics and drug resistance in triple negative breast cancer.

Presenters

  • Margarite Matossian, MD PhD (Tulane University Medical University) Physician-Scientist in the group of Dr. Matthew Burow (Burow Lab). This study was funded by NIH & Krewe de Pink) Patient-Derived Organoids: Translational Oncology research to Interrogate Therapeutic Responses & Drug Resistance
  • Katya Nikolov, MD (Protein Fluidics, Inc.) Senior Application Scientist Automated Assays with Patient-Derived Organoids using the Pu·MA System

 

Margarite and Katya - Jun 2021

Contact Us

Protein Fluidics, Inc.

875 Cowan Road, Suite B,
Burlingame, CA 94010

+1 650 529 5080

info@proteinfluidics.com

#pumasystem  #flowchip  #3dcellassay

Our Company

For Research Use Only. Not for diagnostic use. Protein Fluidics, Protein Fluidics Logo and Pu•MA System are registered trademarks of Protein Fluidics, Inc. in the United States and internationally. All rights reserved. © 2021 PROTEIN FLUIDICS, INC.